In this episode of The Oncology Insights Podcast, Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, shares results from the global MATTERHORN study and what it means for early-stage gastroesophageal cancer treatment. She explains how immunotherapy is shifting the treatment landscape, the real-world challenges of biomarker access, and why surgical collaboration matters. Listen now on all major platforms! "Despite aggressive chemotherapy regimens, the addition of immunotherapy showed improvement in survival and disease-free outcomes." Meet the guest: Dr. Yelena Janjigian https://www.linkedin.com/in/yelena-janjigian-702123100/ is a physician-scientist and Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. Her research focuses on the molecular characterization of gastroesophageal cancers, aiming to bring innovative therapies to patients worldwide. With over 140 publications, she is a global leader in GI oncology. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:52) Introduction (07:46) Immunotherapy in early-stage (10:26) Trial design challenges (15:03) Regional cancer differences (19:00) Tumor biomarker limitations (24:11) Surgery coordination issues (27:29) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/